Phase 3 Recruiting NIH
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Indiana: - IU Health North Hospital — Carmel, Indiana
- Northwest Cancer Center - Crown Point — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
- Parkview Regional Medical Center — Fort Wayne, Indiana
- Northwest Cancer Center - Hobart — Hobart, Indiana
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Indiana: - UChicago Medicine Northwest Indiana — Crown Point, Indiana
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Indiana: - Research Site — Indianapolis, Indiana
Phase 3 Recruiting Industry
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in Indiana: - GSK Investigational Site — Fort Wayne, Indiana
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Indiana: - IU Health North Hospital — Carmel, Indiana
- UChicago Medicine Northwest Indiana — Crown Point, Indiana
- Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- IU Health Methodist Hospital — Indianapolis, Indiana
- Sidney and Lois Eskenazi Hospital — Indianapolis, Indiana
Phase 2 Recruiting NIH
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in Indiana: - Reid Health — Richmond, Indiana
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Indiana: - Community Health Network, Inc. — Indianapolis, Indiana
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Indiana: - Exelixis Clinical Site #4 — Indianapolis, Indiana
Phase 1 Recruiting Industry
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Sponsor: Compass Therapeutics
NCT ID: NCT06150664
Sites in Indiana: - Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana
Phase 1 Recruiting Industry
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injec…
Sponsor: KaliVir Immunotherapeutics
NCT ID: NCT06444815
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Phase 1 Recruiting Academic/Other
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immun…
Sponsor: Pravin T.P Kaumaya
NCT ID: NCT06414733
Sites in Indiana: - Indiana University Melvin & Bren Simon Comprehensive Cancer Center — Indianpolis, Indiana
Phase 4 Recruiting Industry
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them fro…
Sponsor: Pfizer
NCT ID: NCT06952660
Sites in Indiana: - Indiana University Health University Hospital — Indianapolis, Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
- Sidney & Lois Eskenazi Hospital — Indianapolis, Indiana
NA Recruiting Academic/Other
This study is a prospective phase II trial, designed to assess the efficacy and feasibility of adjuvant treatment deintensification guided by ctHPVDNA levels for patients with HPV+OPSCC who undergo transoral surgery and neck dissection.
Sponsor: Indiana University
NCT ID: NCT06915038
Sites in Indiana: - IU Health Joe and Shelly Schwarz Cancer Center — Carmel, Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana